U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal
This article was originally published in The Pink Sheet Daily
NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.
You may also be interested in...
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.
The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.